In Figure 2A, we found that highly expressed MSH6 was linked with poor prognosis of OS (Overall survival) for cancer patients with ACC (P=0.0026), as well as KIRP (P=0.065), BLCA (P=0.008), SARC (Sarcoma) (P=0.015) and LGG (P=0.0056). Here, MSH6 is linked to bladder transitional cell carcinoma.